Skip to main content
NCBI home page
Meta Gene logoLink to Meta Gene
. 2014 Aug 24;2:579–585. doi: 10.1016/j.mgene.2014.07.008

IRS1 gene polymorphisms Gly972Arg and Ala513Pro are not associated with insulin resistance and type 2 diabetes risk in non-obese Turkish population

Hilal Arikoglu a,⁎, Melda Aksoy Hepdogru a,1, Dudu Erkoc Kaya a, Aycan Asik a, Suleyman Hilmi Ipekci b, Funda Iscioglu c
PMCID: PMC4287848  PMID: 25606440

Abstract

Insulin receptor substrate 1 (IRS1), plays a critical role in insulin signaling and its control has an important place in the development of insulin resistance. The tyrosine phosphorylation of IRS1 serves as docking molecules for downstream effectors such as Phosphatidylinositol 3-kinase and phosphotyrosine phosphatase-2. We focused on the Gly972Arg and Ala513Pro variants of the IRS1 gene, since these specific allelic variants are located near the Tyr-Met-X-Met (YMXM) motifs around Tyr987 and Tyr612. Thus, we aimed to investigate the effects of Gly972Arg/Ala513Pro polymorphisms in IRS1 gene on development of insulin resistance and the risk of type 2 diabetes in a non-obese Turkish population. This work included 306 individuals comprising 178 subjects with type 2 diabetes and 128 healthy subjects matched for body mass index. Gly972Arg/Ala513Pro polymorphisms had no effect on type 2 diabetes risk and its phenotypes (P > 0.05). Although IRS1 gene and its variants are associated with type 2 diabetes and insulin resistance in several studies worldwide, our data showed that there is no association between Gly972Arg and Ala513Pro variants in IRS1 and disease in Turkish population.

Keywords: IRS1 gene, İnsulin resistance, Type 2 diabetes, Polymorphisms

Introduction

Insulin is an important determinant of early growth and plays a prominent role in maintaining glucose homeostasis. Insulin, secreted from pancreatic beta (β) cells, exhibits its effects by binding to insulin receptor (IR) on target tissues; leading to the activation of multiple signaling molecules and involving their pathways. Insulin-receptor interaction primarily induces autophosphorylation of tyrosine kinase domain on cytoplasmic surface of the receptor, than phosphorylation of a trio of tyrosine residues of cytosolic insulin receptor substrates (IRS). Subsequently, other signaling molecules such as Phosphatidylinositol 3-kinase (PI3- kinase) and Growth factor receptor-bound protein 2 (GRB2) are recruited leads to the activation of the Akt signaling pathway (mediates many metabolic effects that include glucose and lipid metabolism) and the mitogen-activated protein (MAP) kinase pathway (mediates cell proliferation), respectively (Wing, 2008).

IRS proteins have a similar structure consisting of an NH2-terminal pleckstrin homology (PH) domain adjacent to a phosphotyrosine binding (PTB) domain followed by a variable-length COOH-terminal tail. PH domain is essential for effective IR–IRS1 interactions. On the other hand, the PTB domain interacts directly with the juxtamembrane (JM) domain of the insulin receptors (Voliovitch et al., 1995). The COOH terminus of the IRS proteins contains a series of tyrosine (Tyr) phosphorylation sites (approximately 20 sites) that serve as on/off switches to recruit downstream effector molecules. Tyr residues that bind Src homology 2 (SH2) domains of their effector proteins, located in consensus motifs (YMXM or YXXM). Serine/Threonine (Ser/Thr) phosphorylation sites (about 50 sites) adjacent to these Tyr phosphorylation sites prevent binding of the SH2 domains of these effectors, thus inhibit insulin signaling (Myers and White, 1996). And also, it is suggested that this Ser/Thr phosphorylation may be responsible for tumor necrosis factor-α (TNFα)-mediated development of insulin resistance (Hotamisligil et al., 1996, Reis et al., 2012, Tanti et al., 1994).

Insulin resistance is a condition which the response of the target cells to normal levels of insulin is reduced, and insulin resistance plays a central role in the development of type 2 diabetes, an emerging epidemic of the 21st century.

So far, many polymorphisms described in IRS1 gene, located in 2q36-37, especially Gly972Arg substitution, are shown to be associated with insulin resistance in studies with different several populations and meta-analyses about type 2 diabetes (Aileen et al., 2005, Burguete-Garcia et al., 2010, Celi et al., 2000, Jellema et al., 2003, Martínez-Gómez et al., 2011, Zaman Huri et al., 2012). The single nucleotide polymorphisms (SNPs) Gly972Arg, Pro170Arg and Met209Thr in IRS1 gene have been reported to be associated with a reduction in phosphatidylinositol 3 kinase (PI3K) activity (Yoshimura et al., 1997) and subsequently development of insulin resistance (Armstrong et al., 1996, Garcia et al., 1993, Yoshimura et al., 1997). Additionally, the polymorphisms Gly972Arg and Ala513Pro located near the Tyr-Met-X-Met (YMXM) motifs around Tyr987 and Tyr612 have been noted to influence insulin resistance, hyperinsulinemia and fatty-acid composition of muscles (Garcia et al., 1993).

We investigated that whether these two important variants, Gly972Arg (rs1801278) and Ala513Pro (rs1801276) in IRS1 gene are effective on insulin resistance and/or type 2 diabetes in Turkish in central region of Anatolia.

Materials and methods

Study subjects and assessment

In this study, 306 individuals comprised 178 subjects with type 2 diabetes and 128 healthy subjects matched for age and body mass index (BMI) were enrolled. Type 2 diabetic patients were diagnosed according to the American Diabetes Association diagnostic criteria, were over 35 years old and not using insulin, and having a body mass index (BMI) less than 30. In healthy nondiabetic group, subjects had no history of diabetes in first or second degree relatives. Informed written consent was obtained from each individual before participating into the study. The study was approved by the Ethical Committee of the Faculty of Medicine of Selcuk University.

Fasting plasma glucose, fasting insulin, HbA1C and c-peptide values were measured in both groups. In control group, oral glucose tolerance test (OGTT) was performed. For detecting insulin resistance, the homeostasis model assessment of insulin resistance (HOMA-IR) was calculated formulating as fasting plasma glucose (mmol/l) multiplied by fasting serum insulin (pmol/l) and divided by 22.5. An individual with a HOMA-IR value higher than 2.5 was considered to be resistant to insulin.

Genotyping

Genomic DNA was extracted from peripheral blood leukocytes using the standard SDS and proteinase K procedure. SNPs Gly972Arg and Ala513Pro were genotyped using the PCR-RFLP analyses. The PCR analyses were performed using specific primers for scanning the SNPs Gly972Arg and Ala513Pro. The forward and reverse primers were: 5′AGTCTGGCTACTTGTCTGGC3′ and 5′ATGAGTTGTCCCCGTCAGA3′ for SNP Gly972Arg and 5′CGGTGAGGAGGAGCTAAGCA3′ and 5′GTGGGTAGGCAGGCATCATC3′ for SNP Ala513Pro, respectively. PCR amplification was performed in a 30 μl volume containing 50 ng genomic DNA, 1 × PCR buffer, 0.4 mM of each primer, 0.6 mM deoxyribonucleoside triphosphates, 0.1 units Taq polymerase. PCR reactions were carried out in a thermocycler (Bio-Rad, California, USA) as follows: an initial denaturation at 94 °C for 5 min was followed by 35 cycles of denaturation at 94 °C for 30 s, annealing at 57.2 and 58.4 °C (for Gly972Arg and Ala513Pro, respectively) for 30 s, elongation at 72 °C for 30 s, and final extension at 72 °C for 2 min.

RFLP analyses of the target SNPs Gly972Arg and Ala513Pro were achieved using the restriction enzymes AluI (MBI Fermentas, Vilnius, Lithuania) and DraIII (MBI Fermentas, Vilnius, Lithuania) respectively according to the manufacturers' instructions. The resultant restriction fragments were ascertained on a 3% agarose gel and visualized.

Statistical analysis

Descriptive statistics were obtained for clinical and biochemical characteristics. Initial comparison was performed between patient and control groups using t test. The differences between the case and control groups in terms of genotype distribution or allele frequency were analyzed using Pearson Chi-square test. Also in order to evaluate Hardy–Weinberg equilibrium (HWE) in patient and control groups Chi-square goodness of fit test was carried out. Analyses were performed using dominant, additive, and recessive models. Dominance was defined in terms of allele 2 effects. In dominant allele 2 models, homozygous individuals for allele 1 were compared with carriers of allele 2. In recessive allele 2 models, homozygous individuals for allele 2 were compared with carriers of allele 1. Association between genotypes and type 2 diabetes was tested by conducting a case–control study. Allele frequencies of SNPs in patient and control groups were evaluated using odds ratio (OR). We performed logistic regression analysis by considering not only dominant, additive and recessive models of SNP genotypes but also sex and age.

We also checked if there is any association between genotypes and biochemical characteristics exclusive of type 2 diabetes. Therefore we carried out tests for normality of the biochemical characteristics. Fasting plasma insulin and HOMA-IR variables were skewed and were normalized by square root and log transformations respectively, before analysis. SNP genotypes were coded as 11, 12, and 22, respectively. Then single point (single SNP) regression analysis model was fitted for transformed fasting plasma insulin and HOMA-IR. For the other characteristics such as BMI, c-peptide and HbA1C, Kruskal–Wallis test was performed.

Individuals were classified according to their fasting glucose levels as < 100, 100–125, 126–200, and > 200. Chi-square test was then used to evaluate fasting glucose level-SNP genotype relationship.

All analysis was carried out using SPSS 18.0. In all analyses, a P value < 0.05 was considered statistically significant.

Results

Characteristics of study subjects

Clinical and biochemical characteristics of the individuals are shown in Table 1. Compared to the control subjects, type 2 diabetics had significantly different levels of fasting glucose, fasting insulin, HbA1C, and HOMA-IR (P < 0.05). When OGTT results were evaluated, individuals with fasting plasma glucose levels > 200 at the 2nd hour were considered diabetic, and those with levels in the 140–200 range were considered to have impaired glucose tolerance. These individuals were not included in control group.

Table 1.

Clinical characteristics of study subjects.

Variable Type 2 diabetics Healthy controls P value
Sex (M/F) 178 (110/68) 128 (71/57) 0.27a
Age (years)b 56.13 ± 9.25 41.82 ± 9.55 0.00
BMI (kg/m2)c 26.67 (18.60–35.30) 26 (17.6–34.9) 0.08
Fasting glucose (mg/dL)c 137 (77–526) 91 (58–129) 0.00
Fasting insulin (μU/mL)d 8.33 (7.61–9.08) 7.16 (6.58–7.76) 0.01
HbA1c (%)c 6.8 (6.67–7.5) 5.4 (4.0–5.60) 0.00
c-peptide (ng/mL)c 2.0 (0.50–7.20) 2.13 (0.4–15.7) 0.00
HOMA-IRd 2.82 (2.57–3.10) 1.52 (1.40–1.66) 0.00
Open in a new tab

BMI: Body mass index.

HbA1c: Hemoglobin A1c.

HOMA-IR: Homeostasis model assessment of insulin resistance.

a

X2 test.

b

Values are expressed as means ± SD.

c

Median (Minimum–Maximum).

d

Back transformed mean and 95% CI.

Association study

According to the results of genotyping while Gly972Arg polymorphism was identified as heterozygous genotype in 9 patients (5.06%) and 8 healthy subjects (6.25%), Ala513Pro polymorphism was observed heterozygous genotype in only 2 patients (1.12%) (Table 2). None of these polymorphisms was associated with insulin resistance and type 2 diabetes (P > 0.05). Additionally, both of the polymorphisms had no effect on other phenotypes which are fasting glucose, fasting insulin, c-peptide and HbA1c (P > 0.05). Patient and control groups were in Hardy–Weinberg equilibrium (P > 0.05).

Table 2.

Association study and genotype distribution of SNPs in study groups.

SNP Genotype Type 2 diabetic n (%) Control n (%) Homozygote/heterozygote P value
Gly972Arg GG 169 (94.94) 120 (93.75) > 0.05
GA 9 (5.06) 8 (6.25)
AA – –
Ala513Pro GG 176 (98.88) 128 (100) > 0.05
GC 2 (1.12) –
CC – –
Open in a new tab

Because no individual has homozygous genotype of rare allele for both SNPs, homozygous genotype of common allele was compared with heterozygous genotype.

Discussion

Until recently, several genes were identified as type 2 diabetes risk genes due to known or potential biological functions in insulin secretion, insulin signaling, and adipocyte signaling, etc. by candidate gene approach. One of them was IRS1 which is a central molecule in insulin signaling.

After binding insulin to its receptor, the tyrosine phosphorylation of IRS1 serves as docking molecules for downstream effectors such as PI3K and phosphotyrosine phosphatase 2 (SHP-2). Prolonged insulin stimulation and other stimuli triggered by inducers of insulin resistance activate IRS kinases that phosphorylate IRS1, on Ser/Thr residues (Boura-Halfon and Zick, 2009).

On the other hand, the binding specificity and affinity of the tyrosine phosphorylation sites are important for the response of IRS1 to tyrosine protein kinases, therefore polymorphisms within the tyrosine phosphorylation sites of the protein can alter those interactions (Garcia et al., 1993). Thus, the reduction of tyrosine phosphorylation of IRS1 inhibits downstream signaling of IRS1 (Aguirre et al., 2002). Gly972Arg, Pro170Arg and Met209Thr polymorphisms which are around the tyrosine phosphorylation sites (Garcia et al., 1993, Ogihara et al., 1997), cause defects in tyrosine phosphorylation and have revealed different levels of reduction in PI3K activity (Yoshimura et al., 1997). And also, the Ser892Gly and Thr608Arg polymorphisms were reported in association with decrease in insulin-induced phosphorylation and PI3K activity in type 2 diabetic patients (Laakso et al., 1994).

We investigated the Gly972Arg and Ala513Pro variants of the IRS1 gene, since these specific allelic variants are located near the YMXM motifs around Tyr987 and Tyr612. These variants have been reported to influence insulin resistance, hyperinsulinemia and fatty-acid composition of muscles with a non-sporadic prevalence (Borkman et al., 1993, Garcia et al., 1993). Gly972Arg polymorphism was found to be associated with type 2 diabetes in different populations (Aileen et al., 2005, Burguete-Garcia et al., 2010, Celi et al., 2000, Jellema et al., 2003, Martínez-Gómez et al., 2011, Zaman Huri et al., 2012), whereas several studies reported no relationship between Gly972Arg polymorphism and disease status (Florez et al., 2004, Zeggini et al., 2004). In a study conducted in the Turkish population, common polymorphism Gly972Arg and other rare polymorphisms were reported not to be associated with type 2 diabetes and related phenotypes (Orkunoglu Suer et al., 2005). Our data replicated that there is no association between Gly972Arg and Ala513Pro variants in IRS1 and type 2 diabetes in Turkish population. Only a difference in allele frequency was observed, probably due to larger sample size of our study compared to previous study. Also, we determined Ala513Pro polymorphism in heterozygote form in only two patients while Orkunoglu Suer et al. (2005) detected in only one healthy subject. So, this polymorphism is rare in Turkish population as previously reported in other populations (Celi et al., 2000, Hart et al., 2002).

In our study, although fasting insulin, fasting glucose, HbA1c, c-peptide and HOMA-IR levels were found to be different between patient and healthy groups, both polymorphisms were not associated statistically with these phenotypes.

In recent years, with the contribution of Genome wide association (GWA) studies in type 2 diabetes pathogenesis, it has reached a great number of risk gene/allele, but the molecular mechanisms are mostly unknown. However, only a few risk genes related with type 2 diabetes development which include IRS1 were confirmed by GWA studies (Rung et al., 2009, Voight et al., 2010). Contrary to expectations, the SNP identified in IRS1 gene by GWA study was not Gly972Arg, the associated new SNP (rs2943641) has been located about 500 kb upstream of the IRS1 gene (Rung et al., 2009). The rs2943641 in IRS1 was found to be associated with type 2 diabetes, insulin resistance and hyperinsulinemia in 3 European populations comprised of over 14,000 individuals (Rung et al., 2009). IRS1 gene, G972R and nearby markers detected by candidate gene approach and GWA studies are not in linkage disequilibrium (Rung et al., 2009). In recent years, although it has not reached genome-wide significance, in a large-scale meta-analyses an intronic SNP rs4675095 in IRS1 which is not in LD neither with the SNP G972R (rs1801278) nor with the SNP rs2943641 was also associated with HOMA-IR (P = 4.6 × 10−3) (Dupuis et al., 2010). Furthermore in another meta-analyses performed using a two-stage genome-wide association, including up to 76,150 individuals, Kilpeläinen et al. (2011) identified three loci convincingly associated with body fat percentage. One of them was rs2943650 variant (r2 = 1.00 with rs2943641) located 500 kb upstream of IRS1, an important mediator of insulin and insulin-like growth factor-1 (IGF-1) signaling (Kilpeläinen et al., 2011).

From the perspective of functional analyses, the risk allele was associated with reduced levels of IRS1 protein expression and decreased PI3K activity in human skeletal muscle biopsies (Rung et al., 2009). Null IRS1 (Araki et al., 1994) and tissue-specific knockout (Nandi et al., 2004) experiments in mice have showed that IRS1 is a fundamental factor of insulin action both in peripheral insulin-sensitive tissues and in insulin-secreting pancreatic beta cells.

When the association data of different polymorphisms in IRS1 gene and throughout or near this locus with diabetes evaluated with functional study data; it is clear that this locus is important in terms of affecting IRS1 gene expression, further insulin signaling and type 2 diabetes development. On the other hand, we did not found any association in our population similar to some other populations (Florez et al., 2004, Zeggini et al., 2004). Lack of association in our study is possibly due to multiple different genes and variants thought to be effective in development of insulin resistance and type 2 diabetes.

In conclusion, our results replicated that the IRS1 gene/variants have no contribution on genetic architecture of type 2 diabetes in the Turkish population. Even larger sample sizes will be required to characterize IRS1 gene in Turkish population.

Acknowledgment

We would like to thank to Dr. Ahmet Arslan and Dr. Mustafa Sait Gonen for their assistance in this study. This study was supported by the Selcuk University Research Foundation (2003/010).

Financial disclosure

The authors declared no financial disclosure.

References

  1. Aguirre V., Werner E.D., Giraud J., Lee Y.H., Shoelson S.E., White M.F. Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. J. Biol. Chem. 2002;277:1531–1537. doi: 10.1074/jbc.M101521200. [DOI] [PubMed] [Google Scholar]
  2. Aileen J.M., Edward P.F., Ronald K. Human insulin receptor substrate-1 (IRS-1) polymorphism G972R causes IRS-1 to associate with the insulin receptor and inhibit receptor autophosphorylation. J. Biol. Chem. 2005;280:6441–6446. doi: 10.1074/jbc.M412300200. [DOI] [PubMed] [Google Scholar]
  3. Araki E., Lipes M.A., Patti M.E., Brüning J.C., Haag B., III, Johnson R.S., Kahn C.R. Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. Nature. 1994;372:186–190. doi: 10.1038/372186a0. [DOI] [PubMed] [Google Scholar]
  4. Armstrong M., Haldane F., Avery P.J., Mitcheson J., Stewart M.W., Turnbull D.M., Walker M. Relationship between insulin sensitivity and insulin receptor substrate-1 mutations in non-diabetic relatives of NIDDM families. Diabet. Med. 1996;13:341–345. doi: 10.1002/(SICI)1096-9136(199604)13:4<341::AID-DIA80>3.0.CO;2-F. [DOI] [PubMed] [Google Scholar]
  5. Borkman M., Storlien L.H., Pan D.A., Jenkins A.B., Chisholm D.J., Campbell L.V. The relation between insulin sensitivity and the fatty-acid composition of skeletal-muscle phospholipids. N. Engl. J. Med. 1993;328:238–244. doi: 10.1056/NEJM199301283280404. [DOI] [PubMed] [Google Scholar]
  6. Boura-Halfon S., Zick Y. Phosphorylation of IRS proteins, insulin action, and insulin resistance. Am. J. Physiol. Endocrinol. Metab. 2009;296:e581–e591. doi: 10.1152/ajpendo.90437.2008. [DOI] [PubMed] [Google Scholar]
  7. Burguete-Garcia A.I., Cruz-Lopez M., Madrid-Marina V., Lopez-Ridaura R., Hernández-Avila M., Cortina B., Gómez R.E., Velasco-Mondragón E.E. Association of Gly972Arg polymorphism of IRS-1 gene with type 2 diabetes mellitus in lean participants of a national health survey in Mexico: a candidate gene study. Metabolism. 2010;59:38–45. doi: 10.1016/j.metabol.2009.07.007. [DOI] [PubMed] [Google Scholar]
  8. Celi F.S., Negri C., Tanner K., Raben N., De Pablo F., Rovira A., Pallardo L.F., Martin-Vaquero P., Stern M.P., Mitchell B.D. Molecular scanning for mutations in the insulin receptor subsrtrate-1 (IRS-1) gene in Mexican Americans with type 2 diabetes mellitus. Diabetes Metab. Res. Rev. 2000;16:370–377. doi: 10.1002/1520-7560(2000)9999:9999<::aid-dmrr129>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  9. Dupuis J., Langenberg C., Prokopenko I., Saxena R., Soranzo N., Jackson A.U., Wheeler E., Glazer N.L., Bouatia-Naji N., Gloyn A.L. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat. Genet. 2010;42:105–116. doi: 10.1038/ng.520. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Florez J.C., Sjogren M., Burtt N., Orho-Melander M., Schayer S., Sun M., Almgren P., Lindblad U., Tuomi T., Gaudet D. Association testing in 9,000 people fails to confirm the association of the insulin receptor substrate-1 G972R polymorphism with type 2 diabetes. Diabetes. 2004;53:3313–3318. doi: 10.2337/diabetes.53.12.3313. [DOI] [PubMed] [Google Scholar]
  11. Garcia P., Shoelson S.E., George S.T., Hinds D.A., Goldberg A.R., Miller W.T. Phosphorylation of synthetic peptides containing Tyr-Met-X-Met motifs by nonreceptor tyrosine kinases in vitro. J. Biol. Chem. 1993;268:25146–25151. [PubMed] [Google Scholar]
  12. Hart L.M., Nijpels G., Dekker J.M., Maassen J.A., Robert J., Haeften T.W. Variations in insulin secretion in carriers of gene variants in IRS-1 and -2. Diabetes. 2002;51:884–887. doi: 10.2337/diabetes.51.3.884. [DOI] [PubMed] [Google Scholar]
  13. Hotamisligil G.S., Peraldi P., Budavari A., Ellis R., White M.F., Spiegelman B.M. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity induced insulin resistance. Science. 1996;271:665–668. doi: 10.1126/science.271.5249.665. [DOI] [PubMed] [Google Scholar]
  14. Jellema A., Zeegers M.P., Feskens E.J., Dagnelie P.C., Mensink R.P. Gly972Arg variant in the insulin receptor substrate-1 gene and association with Type 2 diabetes: a meta-analysis of 27 studies. Diabetologia. 2003;46:990–995. doi: 10.1007/s00125-003-1126-4. [DOI] [PubMed] [Google Scholar]
  15. Kilpeläinen T.O., Zillikens M.C., Stančákova A., Finucane F.M., Ried J.S., Langenberg C., Zhang W., Beckmann J.S., Luan J., Vandenput L. Genetic variation near IRS1 associates with reduced adiposity and an impaired metabolic profile. Nat. Genet. 2011;43:753–760. doi: 10.1038/ng.866. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Laakso M., Malkki M., Kekalainen P., Kuusisto J., Deeb S.S. Insulin receptor substrate-1 variants in non-insulin-dependent diabetes. J. Clin. Invest. 1994;94:1141–1146. doi: 10.1172/JCI117429. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Martínez-Gómez L.E., Cruz M., Martínez-Nava G.A., Madrid-Marina V., Parra E., García-Mena J., Espinoza-Rojo M., Estrada-Velasco B.I., Piza-Roman L.F., Aguilera P. A replication study of the IRS1, CAPN10, TCF7L2, and PPARG gene polymorphisms associated with type 2 diabetes in two different populations of Mexico. Ann. Hum. Genet. 2011;75:612–620. doi: 10.1111/j.1469-1809.2011.00668.x. [DOI] [PubMed] [Google Scholar]
  18. Myers M.G., Jr., White M.F. Insulin signal transduction and the IRS proteins. Annu. Rev. Pharmacol. Toxicol. 1996;36:615–658. doi: 10.1146/annurev.pa.36.040196.003151. [DOI] [PubMed] [Google Scholar]
  19. Nandi A., Kitamura Y., Kahn C.R., Accili D. Mouse models of insulin resistance. Physiol. Rev. 2004;84:623–647. doi: 10.1152/physrev.00032.2003. [DOI] [PubMed] [Google Scholar]
  20. Ogihara T., Isobe T., Ichimura T., Taoka M., Funaki M., Sakoda H., Onishi Y., Inukai K., Anai M., Fukushima Y. 14-3-3 protein binds to insulin receptor substrate-1, one of the binding sites of which is in the phosphotyrosine binding domain. J. Biol. Chem. 1997;272:25267–25274. doi: 10.1074/jbc.272.40.25267. [DOI] [PubMed] [Google Scholar]
  21. Orkunoglu Suer F.E., Mergen H., Bolu E., Ozata M. Molecular scanning for mutations in the insulin receptor substrate-1 (Irs-1) gene in Turkish with type 2 diabetes mellitus. Endocr. J. 2005;52:593–598. doi: 10.1507/endocrj.52.593. [DOI] [PubMed] [Google Scholar]
  22. Reis K., Del Valle L., Lassak A., Trojanek J. Nuclear IRS-1 and Cancer. J. Cell. Physiol. 2012;227:2992–3000. doi: 10.1002/jcp.24019. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Rung J., Cauchi S., Albrechtsen A., Shen L., Rocheleau G., Cavalcanti-Proenca C., Bacot F., Balkau B. Genetic variant near IRS1 is associated with type 2 diabetes, insulin resistance and hyperinsulinemia. Nat. Genet. 2009;41:1110–1115. doi: 10.1038/ng.443. [DOI] [PubMed] [Google Scholar]
  24. Tanti J.F., Gremeaux T., van Obberghen E., Le Marchand-Brustel Y. Serine/threonine phosphorylation of insulin receptor substrate 1 modulates insulin receptor signaling. J. Biol. Chem. 1994;269:6051–6057. [PubMed] [Google Scholar]
  25. Voight B.F., Scott L.J., Steinthorsdottir V., Morris A.P., Dina C., Welch R.P., Zeggini E., Huth C., Aulchenko Y.S., Thorleifsson G. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat. Genet. 2010;42:579–589. doi: 10.1038/ng.609. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Voliovitch H., Schindler D.G., Hadari Y.R., Taylor S.I., Accili D., Zick Y. Tyrosine phosphorylation of insulin receptor substrate-1 in vivo depends upon the presence of its pleckstrin homology region. J. Biol. Chem. 1995;270:18083–18087. doi: 10.1074/jbc.270.30.18083. [DOI] [PubMed] [Google Scholar]
  27. Wing S.S. The UPS in diabetes and obesity. BMC Biochem. 2008;9(Suppl. 1):S6. doi: 10.1186/1471-2091-9-S1-S6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Yoshimura R., Araki E., Ura S., Todaka M., Tsuruzoe K., Furukawa N., Motoshima H., Yoshizato K., Kaneko K., Matsuda K. Impact of natural IRS-1 mutations on insulin signals: mutations of IRS-1 in the PTB domain and near SH2 protein binding sites result in impaired function at different steps of IRS-1 signaling. Diabetes. 1997;46:929–936. doi: 10.2337/diab.46.6.929. [DOI] [PubMed] [Google Scholar]
  29. Zaman Huri H., Makmor-Bakry M., Hashim R., Mustafa N., Wan Ngah W.Z. Optimisation of glycaemic control during episodes of severe/acute hyperglycaemia in patients with type 2 diabetes mellitus. Int. J. Clin. Pharm. 2012;34:863–870. doi: 10.1007/s11096-012-9682-7. [DOI] [PubMed] [Google Scholar]
  30. Zeggini E., Parkinson J., Halford S., Owen K.R., Frayling T.M., Walker M., Hitman G.A., Levy J.C., Sampson J., Feskens E.J.M. MI Association studies of insulin receptor substrate 1 gene (IRS1) variants in type 2 diabetes samples enriched for family history and early age of onset. Diabetes. 2004;53:3319–3322. doi: 10.2337/diabetes.53.12.3319. [DOI] [PubMed] [Google Scholar]

Articles from Meta Gene are provided here courtesy of Elsevier

RESOURCES